

# Halozyyme Therapeutics

HyQvia got a favourable vote

Regulatory and  
quarterly update

Pharma & biotech

20 August 2014

**Price** **US\$10.0**  
**Market cap** **US\$1,247m**

Net cash (\$m) at June 2014	147.6
Shares in issue	124.5m
Free float	78.9%
Code	HALO
Primary exchange	NASDAQ
Secondary exchange	N/A

## Share price performance



## Business description

Halozyyme Therapeutics focuses on development of extracellular matrix-based drugs. Its rHuPH20-based delivery platform has been used by partners, including Roche, Baxter and Pfizer, to develop SC injection of IV drugs such as Herceptin, Rituxan (Roche) and GAMMAGARD (Baxter). Its pipeline consists of Hylenex, approved for hydration, PEGPH20 in Phase II trials for pancreatic cancer, and HTI-501 in Phase II trials for cellulite.

## Next events

Potential HyQvia US approval	Q314
Initiation of second PEGPH20 trial	Q414

## Analysts

Jason Zhang PhD	+1 646 653 7027
Dr Mick Cooper	+44 (0)20 3077 5734

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

The positive vote (15 to one) by the FDA's Blood Products Advisory Committee (BPAC) for HyQvia should pave the way for its US approval (Q3) and its launch by Baxter, the drug's commercial partner. Potential risk factors raised and extensively discussed by the FDA at the panel meeting could result in some label restrictions, which will be in line with the drug's restricted approval in the EU. An FDA approval would remove one near-term risk for Halozyyme. The panel vote, though positive, has only a small impact on Halozyyme's valuation, which is now \$1,448m, or \$11.7 per basic share, vs previously \$1,445m, or \$11.6 per basic share.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	42.3	(53.5)	(0.48)	0.0	N/A	N/A
12/13	54.8	(83.5)	(0.74)	0.0	N/A	N/A
12/14e	67.6	(68.4)	(0.55)	0.0	N/A	N/A
12/15e	88.8	(55.7)	(0.44)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

## Favourable vote despite FDA's focus on risks

FDA scientists spent the majority of their time at the panel meeting discussing data of anti-rHuPH20 (recombinant human hyaluronidase) antibodies seen in HyQvia treated patients. Because the nerve systems and sperms of males express high levels of hyaluronidase, raising anti-rHuPH20 antibodies could in theory cause damage to these two tissues. At the end, the panel voted 15 to one recommending the approval of HyQvia based on a favourable risk/benefit profile of the drug. We now project that the FDA will approve the drug in Q3 and as such remove a major near-term overhang of the stock.

## PEGPH20 moving along

Since the restart of the Phase II trial (Study 202) in June, c 75% of the anticipated clinical sites have received independent review board approvals and a number of sites are enrolling new patients of the 200-pt (increased from previously at c 150) pancreatic cancer trial. A new clinical trial for non-small cell lung cancer (NSCLC) will be started before the end of the year.

## Valuation: Small financial impact

Our valuation of Halozyyme has changed slightly to \$1,448m, or \$11.7 per basic share, after we increased our probability of success of HyQvia from 85% to 100% but slowed down the product's ramp. The change in HyQvia parameters resulted in a change of valuation of \$3m, reinforcing our previous assertion that the decision on HyQvia's US approval would have a modest impact on the company's valuation. The bulk of the valuation comes from Herceptin SC, Rituxan SC and PEGPH20 for cancer, and they are not changed at this time. Our valuation suggests there is still upside potential in the stock.

## Valuation

We value Halozyme (Exhibit 1) using our discount cash flow method, evaluating its platform and its own pipeline separately. We forecast PEGPH20 and Hylenex (with pump insulin) sales up to 2027. With a 25% probability of success (taking into consideration of the recent protocol modification of the Phase II) for PEGPH20 and 85% (based on success of the late-stage clinical trial) for Hylenex (with pump insulin), and our standard discount rate of 12.5%, we arrived at risk-adjusted, after tax rNPVs of \$416m and \$336m, respectively. For collaborative products, we focused mainly on Herceptin SC, MabThera SC and HyQvia, as they are either approved or pending approval. Based on our estimates of revenue of these products, 100% probability of success and a 12.5% discount rate, we arrive at an rNPV of \$477m. We also arrive at a value of \$132m for the remaining collaborative products. Adding \$86.3m end of 2014, debt-free cash, we get a total firm value of \$1,448m, or \$11.7 per basic share (\$11.4 per diluted share).

**Exhibit 1: Halozyme valuation model (\$m except for per share data)**

Product	Main Indication	Status	Probability of success	Launch year	Peak sales \$m	Patent protection	Royalty	rNPV \$m
PEGPH20	First-line pancreatic cancer	Phase II	25%	2018	1,510	>2027	Fully own	416
Hylenex (pump insulin)	Type I diabetes	Late-stage	85%	2015	295	>2027	Fully own	336
Herceptin SC	Breast cancer	Approved	100%	2013	1,603	>2027	4%	218
MabThera SC	NHL	Approved	100%	2014	1,403	>2027	4%	181
HyQvia	Primary immune deficiency	Approved/pending	100%	2013	751	>2027	4%	36
Future milestone payments (for above three)			100%	N/A	N/A	N/A	4%	42
Other collaborative products			65%	2018	3,010	>2027	4%	132
Total								1,361
Cash and cash equivalents (YE 14)								86.3
Total firm value								1,448
Total basic shares (m)								124.5
Value per basic share (\$)								11.7
Stock options (as of 31 December 2013, m)								7.4
Cash on exercise								51.7
Total firm value inc proceeds from options								1,499
Total number of shares (m)								131.4
Diluted value per share (\$)								11.4
Source: Edison Investment Research								

## Financials

Halozyme reported a net loss of \$16.3m, with revenue of \$18.4m, SG&A of \$8.8m and R&D of \$18.6m in Q214. Operating cash burn for the quarter was \$15.8m. The company ended the quarter with cash and marketable securities of \$147.6m. As of June 2014, the company carried long-term debt of \$43.6m and deferred revenue of \$48.6m, resulting mainly from milestone payments Halozyme received from its collaborators.

Our forecasts for 2014 and 2015 are not changed materially, including total revenue of \$67.6m, R&D expenses of \$93m, and SG&A of \$32m in 2014. We estimate the company's cash utilisation will be \$50.3m in 2014 and it will end the year with cash and cash equivalents of c \$135.6m, which is sufficient to support the company's clinical development of PEGPH20 and its operation beyond 2015.

**Exhibit 2: Financial summary**

Year end 31 December	\$m	2010	2011	2012	2013	2014e	2015e
		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>							
Revenue		13.6	56.1	42.3	54.8	67.6	88.8
Cost of Sales		(1.0)	(0.3)	(1.1)	(6.2)	(9.5)	(9.6)
Gross Profit		12.6	55.8	41.2	48.6	58.1	79.1
EBITDA		(60.6)	(26.5)	(63.1)	(91.2)	(81.4)	(65.7)
Operating Profit (before amort. and except.)		(54.3)	(19.8)	(53.6)	(80.4)	(66.9)	(53.7)
Intangible Amortisation		0.0	0.0	0.0	0.0	0.0	0.0
Exceptionals		0.0	0.0	0.0	0.0	0.0	0.0
Other		2.0	0.1	0.1	(3.3)	(3.0)	(3.0)
Operating Profit		(52.3)	(19.8)	(53.5)	(83.7)	(69.9)	(56.7)
Net Interest		0.0	0.1	0.1	0.2	1.5	1.0
Profit Before Tax (norm)		(54.2)	(19.7)	(53.5)	(83.5)	(68.4)	(55.7)
Profit Before Tax (FRS 3)		(52.2)	(19.7)	(53.5)	(83.5)	(68.4)	(55.7)
Tax		0.0	0.0	0.0	0.0	0.0	0.0
Profit After Tax (norm)		(52.2)	(19.7)	(53.5)	(83.5)	(68.4)	(55.7)
Profit After Tax (FRS 3)		(52.2)	(19.7)	(53.5)	(83.5)	(68.4)	(55.7)
Average Number of Shares Outstanding (m)		94.36	102.57	111.08	112.81	124.00	126.50
EPS - normalised (\$)		(0.55)	(0.19)	(0.48)	(0.74)	(0.55)	(0.44)
EPS - normalised and fully diluted (\$)		(0.51)	(0.18)	(0.46)	(0.70)	(0.52)	(0.42)
EPS - (IFRS) (\$)		(0.06)	(0.19)	(0.48)	(0.74)	(0.55)	(0.44)
Dividend per share (\$)		0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		92.8	99.5	97.4	88.6	85.9	89.1
EBITDA Margin (%)		N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	N/A	N/A	N/A
<b>BALANCE SHEET</b>							
Fixed Assets		1.8	1.8	3.7	6.6	5.1	5.9
Intangible Assets		0.0	0.0	0.0	0.0	0.0	0.0
Tangible Assets		1.8	1.8	3.7	3.4	3.0	2.5
Investments		0.0	0.0	0.0	3.2	2.1	3.4
Current Assets		89.5	64.0	131.0	95.2	161.7	131.1
Inventory		0.2	0.6	2.7	6.2	6.5	10.0
Accounts receivable, net		2.3	2.3	15.7	9.1	9.5	11.4
Cash and cash equivalents		83.3	52.8	99.9	71.5	135.6	97.6
Other		3.7	8.3	12.8	8.4	10.1	12.1
Current Liabilities		(15.3)	(17.3)	(18.9)	(25.5)	(25.6)	(29.6)
Creditors		(15.3)	(17.3)	(18.9)	(25.5)	(25.6)	(29.6)
Short term borrowings		0.0	0.0	0.0	0.0	0.0	0.0
Long Term Liabilities		(55.7)	(37.6)	(66.9)	(96.3)	(100.3)	(98.8)
Long term borrowings		0.0	0.0	(29.7)	(49.8)	(49.3)	(48.8)
Other long term liabilities		(55.7)	(37.6)	(37.3)	(46.6)	(51.0)	(50.0)
Net Assets		20.4	10.9	48.9	(20.0)	40.9	8.7
<b>CASH FLOW</b>							
Operating Cash Flow		(45.4)	(34.4)	(64.3)	(49.3)	(50.3)	(45.5)
Net Interest		0.0	0.1	0.1	0.2	1.5	1.0
Tax		0.0	0.0	0.0	0.0	0.0	0.0
Capex		(0.6)	(0.8)	(1.4)	(2.3)	0.0	0.0
Acquisitions/disposals		0.0	0.0	0.0	0.0	0.0	0.0
Financing		61.8	4.7	83.2	5.1	114.3	7.5
Dividends		0.0	0.0	0.0	0.0	0.0	0.0
Net Cash Flow		15.8	(30.4)	17.5	(46.3)	65.5	(37.0)
Opening net debt/(cash)		(67.5)	(83.3)	(52.8)	(70.2)	(21.7)	(86.3)
HP finance leases initiated		0.0	0.0	0.0	0.0	0.0	0.0
Other		0.0	(0.1)	(0.1)	(2.2)	(1.0)	(0.5)
Closing net debt/(cash)		(83.3)	(52.8)	(70.2)	(21.7)	(86.3)	(48.8)

Source: Halozyme reports, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Halozyne Therapeutics and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2014. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.